Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Neutralization of SARS-CoV-2 Omicron pseudovirus by BNT162b2 vaccine-elicited human sera

View ORCID ProfileAlexander Muik, Bonny Gaby Lui, Ann-Kathrin Wallisch, Maren Bacher, Julia Mühl, Jonas Reinholz, Orkun Ozhelvaci, Nina Beckmann, Ramón de la Caridad Güimil Garcia, Asaf Poran, Svetlana Shpyro, Hui Cai, Qi Yang, Kena A. Swanson, Özlem Türeci, Ugur Sahin
doi: https://doi.org/10.1101/2021.12.22.21268103
Alexander Muik
1BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexander Muik
Bonny Gaby Lui
1BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann-Kathrin Wallisch
1BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maren Bacher
1BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Mühl
1BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonas Reinholz
1BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orkun Ozhelvaci
1BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nina Beckmann
1BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramón de la Caridad Güimil Garcia
1BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asaf Poran
2BioNTech US; 40 Erie Street, Cambridge, MA, 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Svetlana Shpyro
1BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hui Cai
3Pfizer, 401 N Middletown Rd., Pearl River, NY 10960, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qi Yang
3Pfizer, 401 N Middletown Rd., Pearl River, NY 10960, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kena A. Swanson
3Pfizer, 401 N Middletown Rd., Pearl River, NY 10960, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Özlem Türeci
1BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
4HI-TRON – Helmholtz Institute for Translational Oncology Mainz by DKFZ, Obere Zahlbacherstr. 63, 55131 Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ugur Sahin
1BioNTech, An der Goldgrube 12, 55131 Mainz, Germany
5TRON gGmbH – Translational Oncology at the University Medical Center of the Johannes Gutenberg, University Freiligrathstraße 12, 55131 Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Ugur.Sahin@biontech.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

A new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage, B.1.1.529, was recently detected in Botswana and South Africa and is now circulating globally. Just two days after it was first reported to the World Health Organization (WHO), this strain was classified as a variant of concern (VOC) and named Omicron. Omicron has an unusually large number of mutations, including up to 39 amino acid modifications in the spike (S) protein, raising concerns that its recognition by neutralizing antibodies from convalescent and vaccinated individuals may be severely compromised. In this study, we tested pseudoviruses carrying the SARS-CoV-2 spike glycoproteins of either the Wuhan reference strain, the Beta, the Delta or the Omicron variants of concern with sera of 51 participants that received two doses or a third dose (≥6 months after dose 2) of the mRNA-based COVID-19 vaccine BNT162b2. Immune sera from individuals who received two doses of BNT162b2 had more than 22-fold reduced neutralizing titers against the Omicron as compared to the Wuhan pseudovirus. One month after a third dose of BNT162b2, the neutralization titer against Omicron was increased 23-fold compared to two doses and antibody titers were similar to those observed against the Wuhan pseudovirus after two doses of BNT162b2. These data suggest that a third dose of BNT162b2 may protect against Omicron-mediated COVID-19, but further analyses of longer-term antibody persistence and real-world effectiveness data are needed.

Competing Interest Statement

U.S. and O.T. are management board members and employees at BioNTech SE. A.M., A.W., B.G.L, J.M., J.R., M.B, N.B., O.O., S.S. and R.G. are employees at BioNTech SE. A.P. is an employee at BioNTech US. U.S., O.T. and A.M. are inventors on patents and patent applications related to RNA technology and COVID-19 vaccine. U.S., O.T., A.M., A.W., B.G.L., J.M., J.R. and R.G. have securities from BioNTech SE; H.C., Q.Y., K.A.S. are employees at Pfizer and may have securities from Pfizer.

Funding Statement

This work was supported by BioNTech and Pfizer.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee of the Landesaerztekammer Baden- Wuerttemberg, of the Landesamt fuer Gesundheit und Soziales Geschaeftstelle des Landes Berlin, of the Aerztekammer Schleswig Holstein, of the Medizinische Fakultaet Heidelberg and of the Universitaetsklinikum der Goethe-Universitaet Frankfurt gave ethical approval for this work. In addition, the WCG IRB gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Materials are available from the authors under a material transfer agreement with BioNTech.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 23, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Neutralization of SARS-CoV-2 Omicron pseudovirus by BNT162b2 vaccine-elicited human sera
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Neutralization of SARS-CoV-2 Omicron pseudovirus by BNT162b2 vaccine-elicited human sera
Alexander Muik, Bonny Gaby Lui, Ann-Kathrin Wallisch, Maren Bacher, Julia Mühl, Jonas Reinholz, Orkun Ozhelvaci, Nina Beckmann, Ramón de la Caridad Güimil Garcia, Asaf Poran, Svetlana Shpyro, Hui Cai, Qi Yang, Kena A. Swanson, Özlem Türeci, Ugur Sahin
medRxiv 2021.12.22.21268103; doi: https://doi.org/10.1101/2021.12.22.21268103
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Neutralization of SARS-CoV-2 Omicron pseudovirus by BNT162b2 vaccine-elicited human sera
Alexander Muik, Bonny Gaby Lui, Ann-Kathrin Wallisch, Maren Bacher, Julia Mühl, Jonas Reinholz, Orkun Ozhelvaci, Nina Beckmann, Ramón de la Caridad Güimil Garcia, Asaf Poran, Svetlana Shpyro, Hui Cai, Qi Yang, Kena A. Swanson, Özlem Türeci, Ugur Sahin
medRxiv 2021.12.22.21268103; doi: https://doi.org/10.1101/2021.12.22.21268103

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (899)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8782)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1860)
  • Geriatric Medicine (178)
  • Health Economics (388)
  • Health Informatics (1290)
  • Health Policy (644)
  • Health Systems and Quality Improvement (491)
  • Hematology (207)
  • HIV/AIDS (393)
  • Infectious Diseases (except HIV/AIDS) (10557)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1753)
  • Nursing (103)
  • Nutrition (266)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (461)
  • Oncology (964)
  • Ophthalmology (282)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (219)
  • Psychiatry and Clinical Psychology (1842)
  • Public and Global Health (3982)
  • Radiology and Imaging (654)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (535)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)